For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240712:nRSL2144Wa&default-theme=true
RNS Number : 2144W Eco Animal Health Group PLC 12 July 2024
12 July 2024
ECO Animal Health Group plc
(''ECO" or the "Company")
Investor Presentation covering Full Year Results
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, is pleased to announce that David Hallas, CEO,
and Christopher Wilks, CFO, will be conducting a live presentation covering
the Group's Full Year results for the period ended 31 March 2024.
The online presentation will take place on Tuesday 16 July at 16:00 BST. This
event is open to all existing and potential shareholders and registration is
free. Questions can be submitted during the presentation and will be addressed
at the end of it.
To register for the event, please click here
(https://www.equitydevelopment.co.uk/news-and-events/eco-investor-presentation-16july2024)
.
A video recording of the presentation will be available shortly
afterwards here
(https://www.equitydevelopment.co.uk/news-and-events/eco-investor-presentation-16july2024)
.
Contacts:
ECO Animal Health Group plc 020 8447 8899
David Hallas (CEO)
Christopher Wilks (CFO)
Singer Capital Markets (Nominated Adviser & Joint Broker) 020 7496 3000
Phil Davies
Sam Butcher
Investec (Joint Broker) 020 7597 5970
Gary Clarence
Lydia Zychowska
Equity Development 020 7065 2692
Hannah Crowe
Matt Evans
ICR Consilium (Financial PR) 020 3709 5700
Mary-Jane Elliott ecoanimalhealth@consilium-comms.com
Jessica Hodgson
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.
Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.
Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com/)
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NRAGPUWAMUPCUMP